These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 25384280)

  • 1. To do or not to do: axillary nodal evaluation after ACOSOG Z0011 Trial.
    Humphrey KL; Saksena MA; Freer PE; Smith BL; Rafferty EA
    Radiographics; 2014; 34(7):1807-16. PubMed ID: 25384280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial.
    Giuliano AE; Ballman KV; McCall L; Beitsch PD; Brennan MB; Kelemen PR; Ollila DW; Hansen NM; Whitworth PW; Blumencranz PW; Leitch AM; Saha S; Hunt KK; Morrow M
    JAMA; 2017 Sep; 318(10):918-926. PubMed ID: 28898379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases: Long-term Follow-up From the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 Randomized Trial.
    Giuliano AE; Ballman K; McCall L; Beitsch P; Whitworth PW; Blumencranz P; Leitch AM; Saha S; Morrow M; Hunt KK
    Ann Surg; 2016 Sep; 264(3):413-20. PubMed ID: 27513155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of the American College of Surgeons Oncology Group Z0011 Randomized Trial on the Number of Axillary Nodes Removed for Patients with Early-Stage Breast Cancer.
    Yao K; Liederbach E; Pesce C; Wang CH; Winchester DJ
    J Am Coll Surg; 2015 Jul; 221(1):71-81. PubMed ID: 25899731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolution of axillary nodal staging in breast cancer: clinical implications of the ACOSOG Z0011 trial.
    Shah-Khan M; Boughey JC
    Cancer Control; 2012 Oct; 19(4):267-76. PubMed ID: 23037494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011.
    Lucci A; McCall LM; Beitsch PD; Whitworth PW; Reintgen DS; Blumencranz PW; Leitch AM; Saha S; Hunt KK; Giuliano AE;
    J Clin Oncol; 2007 Aug; 25(24):3657-63. PubMed ID: 17485711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trade-offs associated with axillary lymph node dissection with breast irradiation versus breast irradiation alone in patients with a positive sentinel node in relation to the risk of non-sentinel node involvement: implications of ACOSOG Z0011.
    Krishnan MS; Recht A; Bellon JR; Punglia RS
    Breast Cancer Res Treat; 2013 Feb; 138(1):205-13. PubMed ID: 23338762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of axillary dissection in women with invasive breast cancer who do not fit the Z0011 ACOSOG trial because of three or more metastatic sentinel lymph nodes.
    Bonneau C; Hequet D; Estevez JP; Pouget N; Rouzier R
    Eur J Surg Oncol; 2015 Aug; 41(8):998-1004. PubMed ID: 25986854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Omission of axillary lymph node dissection for clinically node negative early-stage breast cancer patients.
    Kobayashi R; Shiraishi K; Iwase S; Ohtomo K; Nakagawa K
    Breast Cancer; 2015 Nov; 22(6):657-63. PubMed ID: 24756246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative predictors of high and low axillary nodal burden in Z0011 eligible breast cancer patients with a positive lymph node needle biopsy result.
    Lim GH; Upadhyaya VS; Acosta HA; Lim JMA; Allen JC; Leong LCH
    Eur J Surg Oncol; 2018 Jul; 44(7):945-950. PubMed ID: 29705286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does a Positive Axillary Lymph Node Needle Biopsy Result Predict the Need for an Axillary Lymph Node Dissection in Clinically Node-Negative Breast Cancer Patients in the ACOSOG Z0011 Era?
    Pilewskie M; Mautner SK; Stempel M; Eaton A; Morrow M
    Ann Surg Oncol; 2016 Apr; 23(4):1123-8. PubMed ID: 26553439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial.
    Giuliano AE; McCall L; Beitsch P; Whitworth PW; Blumencranz P; Leitch AM; Saha S; Hunt KK; Morrow M; Ballman K
    Ann Surg; 2010 Sep; 252(3):426-32; discussion 432-3. PubMed ID: 20739842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Which sentinel lymph-node (SLN) positive breast cancer patient needs an axillary lymph-node dissection (ALND)--ACOSOG Z0011 results and beyond.
    Gatzemeier W; Mann GB
    Breast; 2013 Jun; 22(3):211-6. PubMed ID: 23478200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Impact of omission of axillary dissection on adjuvant therapy in patients with metastatic sentinel lymph nodes according to the ACOSOG Z0011 criteria].
    Roosen A; Lousquy R; Bricou A; Delpech Y; Selz J; Le Maignan C; Bousquet G; Winterman S; Zelek L; Barranger E
    Gynecol Obstet Fertil; 2014 Jun; 42(6):409-14. PubMed ID: 24861437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The evolving role of axillary lymph node dissection in the modern era of breast cancer management.
    Barry JM; Weber WP; Sacchini V
    Surg Oncol; 2012 Jun; 21(2):143-5. PubMed ID: 21440434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Axillary Dissection and Nodal Irradiation Can Be Avoided for Most Node-positive Z0011-eligible Breast Cancers: A Prospective Validation Study of 793 Patients.
    Morrow M; Van Zee KJ; Patil S; Petruolo O; Mamtani A; Barrio AV; Capko D; El-Tamer M; Gemignani ML; Heerdt AS; Kirstein L; Pilewskie M; Plitas G; Sacchini VS; Sclafani LM; Ho A; Cody HS
    Ann Surg; 2017 Sep; 266(3):457-462. PubMed ID: 28650355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential impact of application of Z0011 derived criteria to omit axillary lymph node dissection in node positive breast cancer patients.
    Verheuvel NC; Voogd AC; Tjan-Heijnen VC; Roumen RM
    Eur J Surg Oncol; 2016 Aug; 42(8):1162-8. PubMed ID: 27265036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The exportability of the ACOSOG Z0011 criteria for omitting axillary lymph node dissection after positive sentinel lymph node biopsy findings: a multicenter study.
    Delpech Y; Bricou A; Lousquy R; Hudry D; Jankowski C; Willecocq C; Thoury A; Loustalot C; Coutant C; Barranger E
    Ann Surg Oncol; 2013 Aug; 20(8):2556-61. PubMed ID: 23456432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in utilization of axillary dissection in women with invasive breast cancer and sentinel node metastasis after the ACOSOG Z0011 trial.
    Tseng J; Alban RF; Siegel E; Chung A; Giuliano AE; Amersi FF
    Breast J; 2021 Mar; 27(3):216-221. PubMed ID: 33586201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is SLN Biopsy Alone Safe in SLN Positive Breast Cancer Patients?
    van la Parra RF; de Wilt JH; Mol SJ; Mulder AH; de Roos WK; Bosscha K
    Breast J; 2015; 21(6):621-6. PubMed ID: 26391102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.